Key Inclusion Criteria:

          -  No evidence of extrahepatic disease

          -  Disease not amenable to curative surgery or transplantation or curative ablation but
             disease amenable to TACE

          -  Child-Pugh score class A to B7 and Eastern Cooperative Oncology Group (ECOG)
             performance status of 0 or 1 at enrollment

          -  Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria

          -  Adequate organ and marrow function

        Key Exclusion Criteria

          -  Any history of nephrotic or nephritic syndrome

          -  Clinically significant cardiovascular disease or history of arterioembolic event
             including a stroke or myocardial infarction, unstable angina, cerebrovascular
             accident, or transient ischemic attack within 6 months prior to randomization

          -  Any prior or current evidence of coagulopathy or bleeding diathesis or patients who
             had any kind of surgery in the past 28 days (biopsies are exempt from this exclusion)

          -  History of abdominal fistula or GI perforation, non healed gastric ulcer that is
             refractory to treatment, or active GI bleeding within 6 months prior to enrollment

          -  Patients with Vp3 and Vp4 portal vein thrombosis on baseline imaging are excluded